Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.65 |
| ▸ | HTR2A | P28223 | 5/20 | 0.65 |
| ▸ | MAOA | P21397 | 8/20 | 0.57 |
| ▸ | MAOB | P27338 | 8/20 | 0.57 |
| ▸ | DRD4 | P21917 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | DRD1 | P21728 | 3/20 | 0.55 |
| ▸ | DRD5 | P21918 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1835185 | 0.99 | DRD2 (0.64) | DRD2HTR2AMAOAMAOBDRD4 | |
| SCHEMBL1837720 | 0.88 | DRD2 (0.61) | DRD2HTR2AMAOAMAOBDRD4 | |
| SCHEMBL1836893 | 0.88 | DRD2 (0.62) | DRD2HTR2AMAOAMAOBDRD4 | |
| SCHEMBL1836340 | 0.88 | DRD2 (0.60) | DRD2HTR2AMAOAMAOBDRD4 | |
| SCHEMBL1836459 | 0.88 | DRD2 (0.63) | DRD2HTR2AMAOAMAOBDRD4 | |
| Hydrochloric Acid SCHEMBL1840787 | 0.87 | DRD2 (0.61) | DRD2HTR2AMAOAMAOBDRD4 | |
| Hydrochloric Acid SCHEMBL1838488 | 0.87 | DRD2 (0.59) | DRD2HTR2AMAOAMAOBDRD4 | |
| Hydrochloric Acid SCHEMBL1839869 | 0.87 | DRD2 (0.62) | DRD2HTR2AMAOAMAOBDRD4 | |
| Hydrochloric Acid SCHEMBL1839058 | 0.87 | DRD2 (0.61) | DRD2HTR2AMAOAMAOBDRD4 | |
| SCHEMBL1840990 | 0.87 | DRD2 (0.68) | DRD2HTR2AMAOAMAOBDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653069-B2 | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-02-18 | — | — | US | claimed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | claimed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | claimed |
| US-8653069-B2 | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia | JIANGSU HENGYI PHARMACEUTICAL CO., LTD. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | JIANGSU GOWORTH INVESTMENT CO. LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2322520-A1 | ARALKYL SUBSTITUTED PIPERIDINE OR PIPERAZINE DERIVATIVES AND THEIR USE FOR TREATING SCHIZOPHRENIA | Jiangsu Guohua Investment Co., Ltd (CN) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160199-A1 | Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia | REN, GRIK5, CAT | DRD2 15/4885HTR2A 425/4885MAOA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.